Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Datopotamab deruxtecan in solid tumors: Recent research progress and clinical applications. | Front Oncol | 2026 | 42482759 | PubTator, text mining | PubMed |
| Antibody-drug conjugates against multidrug-resistant cancers: Biomarker-guided patient selection, payload engineering, linker chemistry, and bystander effects. | Cancer Lett | 2026 | 42480966 | PubTator, text mining | PubMed |
| Sacituzumab govitecan inhibits bone metastases of TROP2-expressing cancers. | Bone | 2026 | 42476483 | PubTator, text mining | PubMed |
| Antibody-drug conjugates in colorectal cancer: advances, challenges, and prospectives. | Biochem Pharmacol | 2026 | 42476270 | PubTator, text mining | PubMed |
| Advances in antibody-drug conjugate-based combination therapy strategies for non-small cell lung cancer. | Expert Opin Biol Ther | 2026 | 42467409 | PubTator, text mining | PubMed |
| The human trophoblast cell-surface antigen 2 (TROP-2) expression on metastasized breast cancer. | J Cancer Res Clin Oncol | 2026 | 42467304 | PubTator, text mining | PubMed |
| Interstitial lung disease in patients treated with antibody-drug conjugates: a review. | Lung Cancer | 2026 | 42462539 | PubTator, text mining | PubMed |
| Folate receptor alpha, TROP2 and HER2 in high-grade serous ovarian cancer: Expression and clinicopathological correlations. | Gynecol Oncol | 2026 | 42447657 | PubTator, text mining | PubMed |
| Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non-Small Cell Lung Cancer: Insights From the EVOKE-01 Study. | Cancer Res Commun | 2026 | 42447505 | PubTator, text mining | PubMed |
| Matriptase proteolysis selectively drives disassembly and internalization of the claudin-7 complex while preserving E-cadherin. | Hum Cell | 2026 | 42440028 | PubTator, text mining | PubMed |
| TROP-2 in solid tumors: From oncogenic driver to therapeutic target with antibody-drug conjugates. | Crit Rev Oncol Hematol | 2026 | 42435952 | PubTator, text mining | PubMed |
| A workflow for assessing antibody-drug conjugate target expression on circulating tumour cells from triple-negative breast cancer and epithelial ovarian cancer patients. | J Liq Biopsy | 2026 | 42433605 | PubTator, text mining | PubMed |
| Is TROP2 ADC ready for EGFR-TKI-resistant NSCLC? | Transl Lung Cancer Res | 2026 | 42433228 | PubTator, text mining | PubMed |
| Impact of trop-2 expression on the efficacy of trop-2-targeted antibody-drug conjugates in metastatic breast cancer: a systematic review and meta-analysis. | J Natl Cancer Inst | 2026 | 42429566 | PubTator, text mining | PubMed |
| Immunohistochemical and molecular diagnostics tailoring personalised ovarian cancer therapy. | Pol J Pathol | 2026 | 42429424 | PubTator, text mining | PubMed |
| Bimodality in pan-cancer proteomics reveals new opportunities for biomarker discovery. | Genome Biol | 2026 | 42426806 | PubTator, text mining | PubMed |
| TROP-2 as a therapeutic target in NSCLC: The promise of Sacituzumab tirumotecan. | Crit Rev Oncol Hematol | 2026 | 42425330 | PubTator, text mining | PubMed |
| Real-world evidence of sacituzumab govitecan in metastatic triple-negative breast cancer: an updated multicenter analysis. | ESMO Open | 2026 | 42413328 | PubTator, text mining | PubMed |
| [Update: Evolution in the management of metastatic urothelial carcinomas]. | Bull Cancer | 2026 | 42409721 | PubTator, text mining | PubMed |
| hIMB1636-LDM, a novel anti-TROP2 ADC, exerts potent antitumor efficacy in pancreatic cancer via direct cytotoxicity and immune activation. | Biochem Pharmacol | 2026 | 42409324 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=5